Predict drug candidate performance before running physical experiments

Preclinical drug development faces critical challenges in stability assessment, cardiac safety screening and membrane permeability testing. Failed candidates in preclinical trials cost time and resources, particularly for biologics like monoclonal antibodies and oligonucleotides, where traditional wet-lab methods struggle to predict formulation behavior.

Simcenter™ Culgi™ software, a key component of the Siemens Xcelerator business platform of software, hardware and services, delivers predictive, multiscale computational chemistry simulations for pharmaceutical R&D teams. This platform enables you to evaluate drug candidates and formulations through in silico modeling before physical testing.

What you can assess with Simcenter Culgi:

• hERG potassium channel interactions for cardiac safety screening
• Lipid membrane permeability of small molecule candidates
• Biologics aggregation and formulation stability
• Crystal polymorph behavior and dissolution properties

The platform integrates into your existing workflows with full traceability from molecular design through preclinical decision making. Simcenter Culgi structures scientific data as AI-ready knowledge, supporting simulation-driven discovery while reducing reliance on costly physical experiments.

Download the fact sheet to learn how computational chemistry accelerates molecule evaluation and formulation design.